帕博利珠-话题@MedSci - williamhill asia

#帕博利珠#

54篇内容 | 1488人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2201607, encodeId=da30220160e9d, content=<a href='/topic/show?id=330410333110' target=_blank style='color:#2F92EE;'>#黑色素瘤#</a> <a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a> <a href='/topic/show?id=a48c1140e924' target=_blank style='color:#2F92EE;'>#抗原RNA疫苗#</a>, objectTitle=读书报告 | Keynote 942研究：个体化新抗原RNA疫苗联合帕博利珠辅助治疗黑色素瘤的IIb期研究, objectType=article, longId=824206, objectId=644c824206dc, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/black-surgeon-giving-instruction-to-medical-team-TMPFGNZ.jpg, objectUrl=/article/show_article.do?id=644c824206dc, replyNumber=0, likeNumber=34, createdTime=2024-05-03, rootId=0, userName=williamhill asia 管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=644c824206dc, moduleTitle=读书报告 | Keynote 942研究：个体化新抗原RNA疫苗联合帕博利珠辅助治疗黑色素瘤的IIb期研究, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=644c824206dc)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2056902, encodeId=adb7205690286, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=Lancet：帕博利珠单抗辅助治疗对II期黑色素瘤具有良好的效果与安全性（KEYNOTE-716）, objectType=article, longId=726015, objectId=0c7fe2601525, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0c7fe2601525, replyNumber=0, likeNumber=87, createdTime=2022-09-14, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0c7fe2601525, moduleTitle=Lancet：帕博利珠单抗辅助治疗对II期黑色素瘤具有良好的效果与安全性（KEYNOTE-716）, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=0c7fe2601525)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056903, encodeId=7c112056903b7, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=Thorac Cancer：Pembrolizumab（帕博利珠单抗）单药一线治疗PD-L1高表达老年NSCLC的疗效, objectType=article, longId=726424, objectId=b321e2642494, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b321e2642494, replyNumber=0, likeNumber=91, createdTime=2022-08-24, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b321e2642494, moduleTitle=Thorac Cancer：Pembrolizumab（帕博利珠单抗）单药一线治疗PD-L1高表达老年NSCLC的疗效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=b321e2642494)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056895, encodeId=2b532056895b4, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=Oncologist：Pembrolizumab（帕博利珠单抗）联合CAPOX（奥沙利铂+卡培他滨）治疗晚期胆管癌（BTC）的疗效和安全性, objectType=article, longId=301205, objectId=7d6a3012059f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d6a3012059f, replyNumber=0, likeNumber=76, createdTime=2022-12-24, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d6a3012059f, moduleTitle=Oncologist：Pembrolizumab（帕博利珠单抗）联合CAPOX（奥沙利铂+卡培他滨）治疗晚期胆管癌（BTC）的疗效和安全性, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=7d6a3012059f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056899, encodeId=2fd6205689947, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=Cancer：帕博利珠单抗对比紫杉醇作为二线治疗亚洲晚期PD-L1阳性(CPS≧1)胃/胃食管交界处(GEJ)癌患者的疗效（KEYNOTE-063）, objectType=article, longId=723564, objectId=5743e2356484, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5743e2356484, replyNumber=0, likeNumber=71, createdTime=2023-03-21, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5743e2356484, moduleTitle=Cancer：帕博利珠单抗对比紫杉醇作为二线治疗亚洲晚期PD-L1阳性(CPS≧1)胃/胃食管交界处(GEJ)癌患者的疗效（KEYNOTE-063）, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=5743e2356484)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056896, encodeId=0b9020568960b, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=帕博利珠单抗用于辅助治疗IB-IIIA期非小细胞肺癌（NSCLC）患者的研究数据公布, objectType=article, longId=295920, objectId=7e81295920f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e81295920f9, replyNumber=0, likeNumber=62, createdTime=2022-12-08, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e81295920f9, moduleTitle=帕博利珠单抗用于辅助治疗IB-IIIA期非小细胞肺癌（NSCLC）患者的研究数据公布, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=7e81295920f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056892, encodeId=90b82056892ea, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=J Clin Oncol：Afatinib（阿法替尼）联合Pembrolizumab（帕博利珠单抗）治疗复发或转移性头颈鳞状细胞癌（HNSCC）患者的疗效：ALPHA研究, objectType=article, longId=294454, objectId=3f302944546a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f302944546a, replyNumber=0, likeNumber=73, createdTime=2022-02-21, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f302944546a, moduleTitle=J Clin Oncol：Afatinib（阿法替尼）联合Pembrolizumab（帕博利珠单抗）治疗复发或转移性头颈鳞状细胞癌（HNSCC）患者的疗效：ALPHA研究, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=3f302944546a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056891, encodeId=c90020568911c, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=J Clin Oncol：KEYNOTE-158研究表明Pembrolizumab（帕博利珠单抗）治疗经治MSI-H/dMMR子宫内膜癌患者疗效显著, objectType=article, longId=293562, objectId=0e1f293562ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0e1f293562ed, replyNumber=0, likeNumber=60, createdTime=2022-12-18, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0e1f293562ed, moduleTitle=J Clin Oncol：KEYNOTE-158研究表明Pembrolizumab（帕博利珠单抗）治疗经治MSI-H/dMMR子宫内膜癌患者疗效显著, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=0e1f293562ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056886, encodeId=0f5e20568861a, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=Gastric Cancer：帕博利珠单抗（Pembrolizumab）vs 紫杉醇治疗既往治疗过PD-L1阳性胃或胃食管连接处癌的疗效：III期临床研究KEYNOTE‑061的2年更新结果, objectType=article, longId=216988, objectId=2a7f21698850, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a7f21698850, replyNumber=0, likeNumber=74, createdTime=2021-10-16, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a7f21698850, moduleTitle=Gastric Cancer：帕博利珠单抗（Pembrolizumab）vs 紫杉醇治疗既往治疗过PD-L1阳性胃或胃食管连接处癌的疗效：III期临床研究KEYNOTE‑061的2年更新结果, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=2a7f21698850)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056894, encodeId=f179205689426, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=Clin Cancer Res：帕博利珠单抗新辅助和辅助治疗可切除局部晚期头颈部鳞状细胞癌患者的疗效, objectType=article, longId=300287, objectId=836930028e24, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=836930028e24, replyNumber=0, likeNumber=61, createdTime=2022-07-15, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=836930028e24, moduleTitle=Clin Cancer Res：帕博利珠单抗新辅助和辅助治疗可切除局部晚期头颈部鳞状细胞癌患者的疗效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=836930028e24)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056900, encodeId=f9012056900ff, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=AACR 2022：围手术期帕博利珠单抗联合卡培他滨和奥沙利铂及辅助帕博利珠单抗治疗可切除胃和胃食管结合部(GC/GEJ)腺癌的II期试验, objectType=article, longId=724028, objectId=b171e24028fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b171e24028fa, replyNumber=0, likeNumber=52, createdTime=2022-07-04, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b171e24028fa, moduleTitle=AACR 2022：围手术期帕博利珠单抗联合卡培他滨和奥沙利铂及辅助帕博利珠单抗治疗可切除胃和胃食管结合部(GC/GEJ)腺癌的II期试验, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=b171e24028fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056898, encodeId=7cec2056898aa, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=ESMO：帕博利珠单抗降低完全切除、早期非小细胞肺癌24%复发或死亡风险（KEYNOTE-091）, objectType=article, longId=301715, objectId=f4ef301e1547, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4ef301e1547, replyNumber=0, likeNumber=78, createdTime=2023-01-21, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4ef301e1547, moduleTitle=ESMO：帕博利珠单抗降低完全切除、早期非小细胞肺癌24%复发或死亡风险（KEYNOTE-091）, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=f4ef301e1547)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056897, encodeId=87f4205689eef, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=Front Oncol：真实世界评估PD-L1≧50%的晚期NSCLC患者一线pembrolizumab（帕博利珠单抗）单药治疗的长期疗效, objectType=article, longId=301707, objectId=d31c301e07bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d31c301e07bd, replyNumber=0, likeNumber=64, createdTime=2023-01-05, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d31c301e07bd, moduleTitle=Front Oncol：真实世界评估PD-L1≧50%的晚期NSCLC患者一线pembrolizumab（帕博利珠单抗）单药治疗的长期疗效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=d31c301e07bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056901, encodeId=9cf4205690116, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=AACR重磅：帕博利珠单抗加卡培他滨和奥沙利铂及辅助帕博利珠单抗治疗可切除的胃和胃食管交界处（GC/GEJ）腺癌的II期试验, objectType=article, longId=723982, objectId=1388e239827e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1388e239827e, replyNumber=0, likeNumber=61, createdTime=2022-10-22, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1388e239827e, moduleTitle=AACR重磅：帕博利珠单抗加卡培他滨和奥沙利铂及辅助帕博利珠单抗治疗可切除的胃和胃食管交界处（GC/GEJ）腺癌的II期试验, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=1388e239827e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056893, encodeId=6c782056893a1, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=Transl Lung Cancer Res: Pembrolizumab（帕博利珠单抗）单药或联合治疗晚期非小细胞肺癌伴骨转移患者的疗效, objectType=article, longId=295254, objectId=ccd329525402, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ccd329525402, replyNumber=0, likeNumber=72, createdTime=2022-11-14, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ccd329525402, moduleTitle=Transl Lung Cancer Res: Pembrolizumab（帕博利珠单抗）单药或联合治疗晚期非小细胞肺癌伴骨转移患者的疗效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=ccd329525402)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056887, encodeId=d44f205688e52, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=J Immunother Cancer：Pembrolizumab（帕博利珠单抗）联合低剂量卡铂治疗复发铂耐药的卵巢、输卵管、原发性腹膜癌的疗效, objectType=article, longId=217313, objectId=046121e3130e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=046121e3130e, replyNumber=0, likeNumber=96, createdTime=2021-12-16, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=046121e3130e, moduleTitle=J Immunother Cancer：Pembrolizumab（帕博利珠单抗）联合低剂量卡铂治疗复发铂耐药的卵巢、输卵管、原发性腹膜癌的疗效, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=046121e3130e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056889, encodeId=a651205688933, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=Front Oncol：贝伐单抗或帕博利珠单抗联合培美曲塞+铂类化疗一线治疗驱动基因阴性晚期非鳞非小细胞肺癌(NSCLC)的直接疗效对比, objectType=article, longId=217997, objectId=faae21e997e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=faae21e997e8, replyNumber=0, likeNumber=69, createdTime=2022-01-16, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=faae21e997e8, moduleTitle=Front Oncol：贝伐单抗或帕博利珠单抗联合培美曲塞+铂类化疗一线治疗驱动基因阴性晚期非鳞非小细胞肺癌(NSCLC)的直接疗效对比, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=faae21e997e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056884, encodeId=e4c5205688454, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=J Clin Oncol: 帕博利珠单抗+GVD（吉西他滨、长春瑞宾和脂质体阿霉素）二线治疗复发或难治性经典霍奇金淋巴瘤的疗效和安全性, objectType=article, longId=213317, objectId=1fc021331e00, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1fc021331e00, replyNumber=0, likeNumber=80, createdTime=2022-04-13, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1fc021331e00, moduleTitle=J Clin Oncol: 帕博利珠单抗+GVD（吉西他滨、长春瑞宾和脂质体阿霉素）二线治疗复发或难治性经典霍奇金淋巴瘤的疗效和安全性, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=1fc021331e00)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056878, encodeId=501920568e895, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=帕博利珠单抗获批新增剂量方案适用在华获批的6个适应证, objectType=article, longId=208569, objectId=942c20856917, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=942c20856917, replyNumber=0, likeNumber=59, createdTime=2021-03-26, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=942c20856917, moduleTitle=帕博利珠单抗获批新增剂量方案适用在华获批的6个适应证, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=942c20856917)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2056890, encodeId=2c27205689070, content=<a href='/topic/show?id=7ca2484816b' target=_blank style='color:#2F92EE;'>#帕博利珠#</a>, objectTitle=帕博利珠单抗在晚期非小细胞肺癌免疫治疗的夺金之路, objectType=article, longId=220767, objectId=af5a220e670b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af5a220e670b, replyNumber=0, likeNumber=51, createdTime=2022-05-20, rootId=0, userName=yankaienglish, userId=8ebc122, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af5a220e670b, moduleTitle=帕博利珠单抗在晚期非小细胞肺癌免疫治疗的夺金之路, moduleType=article, hrefUrl=//www.nyrain.com/article/show_article.do?id=af5a220e670b)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] williamhill asia 话题小助手

帕博利珠

2020-05-29

williamhill asia 管理员 (审核中...)

前往app查看评论内容

#黑色素瘤# #帕博利珠# #抗原RNA疫苗#

读书报告 | Keynote 942研究：个体化新抗原RNA疫苗联合帕博利珠辅助治疗黑色素瘤的IIb期研究

2024-05-03发表于上海

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

Lancet：帕博利珠单抗辅助治疗对II期黑色素瘤具有良好的效果与安全性（KEYNOTE-716）

2022-09-14

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

Thorac Cancer：Pembrolizumab（帕博利珠单抗）单药一线治疗PD-L1高表达老年NSCLC的疗效

2022-08-24

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

Oncologist：Pembrolizumab（帕博利珠单抗）联合CAPOX（奥沙利铂+卡培他滨）治疗晚期胆管癌（BTC）的疗效和安全性

2022-12-24

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

Cancer：帕博利珠单抗对比紫杉醇作为二线治疗亚洲晚期PD-L1阳性(CPS≧1)胃/胃食管交界处(GEJ)癌患者的疗效（KEYNOTE-063）

2023-03-21

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

帕博利珠单抗用于辅助治疗IB-IIIA期非小细胞肺癌（NSCLC）患者的研究数据公布

2022-12-08

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

J Clin Oncol：Afatinib（阿法替尼）联合Pembrolizumab（帕博利珠单抗）治疗复发或转移性头颈鳞状细胞癌（HNSCC）患者的疗效：ALPHA研究

2022-02-21

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

J Clin Oncol：KEYNOTE-158研究表明Pembrolizumab（帕博利珠单抗）治疗经治MSI-H/dMMR子宫内膜癌患者疗效显著

2022-12-18

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

Gastric Cancer：帕博利珠单抗（Pembrolizumab）vs 紫杉醇治疗既往治疗过PD-L1阳性胃或胃食管连接处癌的疗效：III期临床研究KEYNOTE‑061的2年更新结果

2021-10-16

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

Clin Cancer Res：帕博利珠单抗新辅助和辅助治疗可切除局部晚期头颈部鳞状细胞癌患者的疗效

2022-07-15

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

AACR 2022：围手术期帕博利珠单抗联合卡培他滨和奥沙利铂及辅助帕博利珠单抗治疗可切除胃和胃食管结合部(GC/GEJ)腺癌的II期试验

2022-07-04

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

ESMO：帕博利珠单抗降低完全切除、早期非小细胞肺癌24%复发或死亡风险（KEYNOTE-091）

2023-01-21

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

Front Oncol：真实世界评估PD-L1≧50%的晚期NSCLC患者一线pembrolizumab（帕博利珠单抗）单药治疗的长期疗效

2023-01-05

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

AACR重磅：帕博利珠单抗加卡培他滨和奥沙利铂及辅助帕博利珠单抗治疗可切除的胃和胃食管交界处（GC/GEJ）腺癌的II期试验

2022-10-22

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

Transl Lung Cancer Res: Pembrolizumab（帕博利珠单抗）单药或联合治疗晚期非小细胞肺癌伴骨转移患者的疗效

2022-11-14

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

J Immunother Cancer：Pembrolizumab（帕博利珠单抗）联合低剂量卡铂治疗复发铂耐药的卵巢、输卵管、原发性腹膜癌的疗效

2021-12-16

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

Front Oncol：贝伐单抗或帕博利珠单抗联合培美曲塞+铂类化疗一线治疗驱动基因阴性晚期非鳞非小细胞肺癌(NSCLC)的直接疗效对比

2022-01-16

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

J Clin Oncol: 帕博利珠单抗+GVD（吉西他滨、长春瑞宾和脂质体阿霉素）二线治疗复发或难治性经典霍奇金淋巴瘤的疗效和安全性

2022-04-13

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

帕博利珠单抗获批新增剂量方案适用在华获批的6个适应证

2021-03-26

yankaienglish (审核中...)

前往app查看评论内容

#帕博利珠#

帕博利珠单抗在晚期非小细胞肺癌免疫治疗的夺金之路

2022-05-20

科室
- - 订阅+
  - 更多科室
工具
服务